Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 350516, 13 pages
http://dx.doi.org/10.1155/2014/350516
Review Article

Resveratrol as a Therapeutic Agent for Alzheimer’s Disease

1Department of Neurology, Qingdao Hiser Hospital, School of Medicine, Qingdao University, Qingdao 266034, China
2Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China
3Department of Neurology, Qingdao Municipal Hospital, College of Medicine and Pharmaceutics, Ocean University of China, Qingdao 266003, China

Received 6 February 2014; Revised 16 August 2014; Accepted 7 September 2014; Published 26 November 2014

Academic Editor: Raymond Chuen-Chung Chang

Copyright © 2014 Teng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001. View at Google Scholar · View at Scopus
  2. A. Granzotto and P. Zatta, “Resveratrol acts not through Anti-Aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity,” PLoS ONE, vol. 6, no. 6, Article ID e21565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Yaffe, “Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results,” JAMA—Journal of the American Medical Association, vol. 304, no. 17, pp. 1952–1953, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Allain, D. Bentué-Ferrer, O. Tribut, S. Gauthier, B.-F. Michel, and C. D.-L. Rochelle, “Alzheimer's disease: the pharmacological pathway,” Fundamental and Clinical Pharmacology, vol. 17, no. 4, pp. 419–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Kim, H. J. Lee, and K. W. Lee, “Naturally occurring phytochemicals for the prevention of Alzheimer's disease,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1415–1430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Li, Q. Gong, H. Dong, and J. Shi, “Resveratrol, a neuroprotective supplement for Alzheimer's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 27–33, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Ferrières, “The French paradox: lessons for other countries,” Heart, vol. 90, no. 1, pp. 107–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Saiko, A. Szakmary, W. Jaeger, and T. Szekeres, “Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?” Mutation Research—Reviews in Mutation Research, vol. 658, no. 1-2, pp. 68–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Oomen, E. Farkas, V. Roman, E. M. van der Beek, P. G. M. Luiten, and P. Meerlo, “Resveratrol preserves cerebrovascular density and cognitive function in aging mice,” Frontiers in Aging Neuroscience, vol. 1, p. 4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. P. Perl, “Neuropathology of Alzheimer's disease,” Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 32–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Hardy, “Alzheimer's disease: the amyloid cascade hypothesis—an update and reappraisal,” Journal of Alzheimer's Disease, vol. 9, no. 3 supplement, pp. 151–153, 2006. View at Google Scholar · View at Scopus
  13. E. D. Roberson and L. Mucke, “100 Years and counting: prospects for defeating Alzheimer's disease,” Science, vol. 314, no. 5800, pp. 781–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Nunomura, “Oxidative stress hypothesis for Alzheimer's disease and its potential therapeutic implications,” Rinsho Shinkeigaku, vol. 53, no. 11, pp. 1043–1045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. A. Abolfathi, D. Mohajeri, A. Rezaie, and M. Nazeri, “Protective effects of green tea extract against hepatic tissue injury in streptozotocin-induced diabetic rats,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 740671, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. T. Heneka and M. K. O'Banion, “Inflammatory processes in Alzheimer's disease,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 69–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Capiralla, V. Vingtdeux, H. Zhao et al., “Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade,” Journal of Neurochemistry, vol. 120, no. 3, pp. 461–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Velez-Pardo, G. Garcia Ospina, and M. Jimenez del Rio, “Aβ[25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-κB, p53 and c-Jun,” NeuroToxicology, vol. 23, no. 3, pp. 351–365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. G. Tansey, M. K. McCoy, and T. C. Frank-Cannon, “Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention,” Experimental Neurology, vol. 208, no. 1, pp. 1–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Liu, L. Qin, B. C. Wilson, L. An, J.-S. Hong, and B. Liu, “Inhibition by naloxone stereoisomers of β-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 3, pp. 1212–1219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. O. B. Villaflores, Y.-J. Chen, C.-P. Chen, J.-M. Yeh, and T.-Y. Wu, “Curcuminoids and resveratrol as anti-Alzheimer agents,” Taiwanese Journal of Obstetrics and Gynecology, vol. 51, no. 4, pp. 515–525, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. del C. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal, “Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6923–6928, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. A. D. C. Alonso, B. Li, I. Grundke-Iqbal, and K. Iqbal, “Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies,” Current Alzheimer Research, vol. 5, no. 4, pp. 375–384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Iqbal, F. Liu, C.-X. Gong, and I. Grundke-Iqbal, “Tau in Alzheimer disease and related tauopathies,” Current Alzheimer research, vol. 7, no. 8, pp. 656–664, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. M. Wilcock, N. Gharkholonarehe, W. E. van Nostrand, J. Davis, M. P. Vitek, and C. A. Colton, “Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease,” Journal of Neuroscience, vol. 29, no. 25, pp. 7957–7965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Holtzman, “Alzheimer's disease: moving towards a vaccine,” Nature, vol. 454, no. 7203, pp. 418–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. G. R. Mallucci, M. D. White, M. Farmer et al., “Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice,” Neuron, vol. 53, no. 3, pp. 325–335, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. G. M. Pasinetti, J. Wang, P. Marambaud et al., “Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders,” Experimental Neurology, vol. 232, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Wang, L. Ho, Z. Zhao et al., “Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer's disease,” The FASEB Journal, vol. 20, no. 13, pp. 2313–2320, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. P. Cleary, D. M. Walsh, J. J. Hofmeister et al., “Natural oligomers of the amyloid-β protein specifically disrupt cognitive function,” Nature Neuroscience, vol. 8, no. 1, pp. 79–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Wang, L. Ho, W. Zhao et al., “Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 28, no. 25, pp. 6388–6392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. T. Jeon, E. A. Jeong, H. J. Shin et al., “Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet,” Diabetes, vol. 61, no. 6, pp. 1444–1454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Dasgupta and J. Milbrandt, “Resveratrol stimulates AMP kinase activity in neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 17, pp. 7217–7222, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Sharma and Y. K. Gupta, “Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats,” Life Sciences, vol. 71, no. 21, pp. 2489–2498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Kumar, P. S. Naidu, N. Seghal, and S. S. V. Padi, “Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats,” Pharmacology, vol. 79, no. 1, pp. 17–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Schmatz, C. M. Mazzanti, R. Spanevello et al., “Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 610, no. 1–3, pp. 42–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rahvar, M. Nikseresht, S. M. Shafiee et al., “Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain,” Neurochemical Research, vol. 36, no. 5, pp. 761–765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Kim, M. D. Nguyen, M. M. Dobbin et al., “SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis,” The EMBO Journal, vol. 26, no. 13, pp. 3169–3179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. E. O. Lee, H. J. Park, J. L. Kang, H.-S. Kim, and Y. H. Chong, “Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1477–1487, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. B. Ju, O. C. Soon, S.-H. Choi et al., “Neuroprotective effect of Smilacis chinae rhizome on NMDA-induced neurotoxicity in vitro and focal cerebral ischemia in vivo,” Journal of Pharmacological Sciences, vol. 106, no. 1, pp. 68–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. S. Han, W. H. Zheng, S. Bastianetto, J. G. Chabot, and R. Quirion, “Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C,” British Journal of Pharmacology, vol. 141, no. 6, pp. 997–1005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Bastianetto, W.-H. Zheng, and R. Quirion, “Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons,” British Journal of Pharmacology, vol. 131, no. 4, pp. 711–720, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Candelario-Jalil, A. C. P. de Oliveira, S. Gräf et al., “Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia,” Journal of Neuroinflammation, vol. 4, article 25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. A. Kim, S.-Y. Lim, S.-H. Rhee et al., “Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells,” International Journal of Molecular Medicine, vol. 17, no. 6, pp. 1069–1075, 2006. View at Google Scholar · View at Scopus
  47. J.-H. Jang and Y.-J. Surh, “Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death,” Free Radical Biology and Medicine, vol. 34, no. 8, pp. 1100–1110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. A. R. Ladiwala, J. C. Lin, S. S. Bale et al., “Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers,” Journal of Biological Chemistry, vol. 285, no. 31, pp. 24228–24237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. K. J. Kwon, H.-J. Kim, C. Y. Shin, and S.-H. Han, “Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein Kinase pathways,” Journal of Clinical Neurology, vol. 6, no. 3, pp. 127–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Marambaud, H. Zhao, and P. Davies, “Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides,” The Journal of Biological Chemistry, vol. 280, no. 45, pp. 37377–37382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Spanier, H. Xu, N. Xia et al., “Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4),” Journal of Physiology and Pharmacology, vol. 60, pp. 111–116, 2009. View at Google Scholar · View at Scopus
  52. Y. Feng, X. P. Wang, S. G. Yang et al., “Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation,” Neurotoxicology, vol. 30, no. 6, pp. 986–995, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Wendeburg, A. C. P. de Oliveira, H. S. Bhatia, E. Candelario-Jalil, and B. L. Fiebich, “Resveratrol inhibits prostaglandin formation in IL-1β-stimulated SK-N-SH neuronal cells,” Journal of Neuroinflammation, vol. 6, article 26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Albani, L. Polito, S. Batelli et al., “The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α-synuclein or amyloid-β (1-42) peptide,” Journal of Neurochemistry, vol. 110, no. 5, pp. 1445–1456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. V. Vingtdeux, L. Giliberto, H. Zhao et al., “AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism,” The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9100–9113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. D. J. Bonda, H.-G. Lee, A. Camins et al., “The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations,” The Lancet Neurology, vol. 10, no. 3, pp. 275–279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Beher, J. Wu, S. Cumine et al., “Resveratrol is not a direct activator of sirt1 enzyme activity,” Chemical Biology and Drug Design, vol. 74, no. 6, pp. 619–624, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Zhang, J. Liu, and J.-S. Shi, “Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Kumar, S. S. V. Padi, P. S. Naidu, and A. Kumar, “Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms,” Behavioural Pharmacology, vol. 17, no. 5-6, pp. 485–492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. J.-F. Ge, J.-P. Qiao, C.-C. Qi, C.-W. Wang, and J.-N. Zhou, “The binding of resveratrol to monomer and fibril amyloid beta,” Neurochemistry International, vol. 61, no. 7, pp. 1192–1201, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Ferretta, A. Gaballo, P. Tanzarella et al., “Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1842, no. 7, pp. 902–915, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. T.-K. Lin, S.-D. Chen, Y.-C. Chuang et al., “Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy,” International Journal of Molecular Sciences, vol. 15, no. 1, pp. 1625–1646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. M. M. Khan, A. Ahmad, T. Ishrat et al., “Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease,” Brain Research, vol. 1328, pp. 139–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. D. D. Lofrumento, G. Nicolardi, A. Cianciulli et al., “Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses,” Innate Immunity, vol. 20, no. 3, pp. 249–260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Wu, X. Li, J. X. Zhu et al., “Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease,” NeuroSignals, vol. 19, no. 3, pp. 163–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Song, L. Chen, X. Zhang, J. Li, and W. Le, “Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1G93A mouse model of amyotrophic lateral sclerosis,” BioMed Research International, vol. 2014, Article ID 483501, 10 pages, 2014. View at Publisher · View at Google Scholar
  67. R. Mancuso, J. del Valle, L. Modol et al., “Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice,” Neurotherapeutics, vol. 11, no. 2, pp. 419–432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Wang, Y. Zhang, L. Tang, N. Zhang, and D. Fan, “Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis,” Neuroscience Letters, vol. 503, no. 3, pp. 250–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Walle, “Bioavailability of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Ponzo, L. Soldati, and S. Bo, “Resveratrol: a supplementation for men or for mice?” Acta Veterinaria Scandinavica, vol. 12, article 158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. T. S. Anekonda, “Resveratrol—a boon for treating Alzheimer's disease?” Brain Research Reviews, vol. 52, no. 2, pp. 316–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. J. M. López-Nicolás and F. García-Carmona, “Aggregation state and pKa values of (E)-resveratrol as determined by fluorescence spectroscopy and UV-visible absorption,” Journal of Agricultural and Food Chemistry, vol. 56, no. 17, pp. 7600–7605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. L. Frozza, A. Bernardi, K. Paese et al., “Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats,” Journal of Biomedical Nanotechnology, vol. 6, no. 6, pp. 694–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. M. J. Amiot, B. Romier, T.-M. Anh Dao et al., “Optimization of trans-Resveratrol bioavailability for human therapy,” Biochimie, vol. 95, no. 6, pp. 1233–1238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Y. Kang, J. K. Lee, O. Choi et al., “Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E. coli,” BMC Biotechnology, vol. 14, no. 1, article 67, 2014. View at Publisher · View at Google Scholar
  76. A. Amri, J. C. Chaumeil, S. Sfar, and C. Charrueau, “Administration of resveratrol: what formulation solutions to bioavailability limitations?” Journal of Controlled Release, vol. 158, no. 2, pp. 182–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Das, K.-Y. Ng, and P. C. Ho, “Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol,” AAPS PharmSciTech, vol. 11, no. 2, pp. 729–742, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Das and K.-Y. Ng, “Resveratrol-loaded calcium-pectinate beads: effects of formulation parameters on drug release and bead characteristics,” Journal of Pharmaceutical Sciences, vol. 99, no. 2, pp. 840–860, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Peng, H. Xiong, J. Li et al., “Vanillin cross-linked chitosan microspheres for controlled release of resveratrol,” Food Chemistry, vol. 121, no. 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Das, K. Y. Ng, and P. C. Ho, “Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations,” Journal of Drug Targeting, vol. 19, no. 6, pp. 446–457, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. J. R. Moyano-Mendez, G. Fabbrocini, D. de Stefano et al., “Enhanced antioxidant effect of trans-resveratrol: potential of binary systems with polyethylene glycol and cyclodextrin,” Drug Development and Industrial Pharmacy, vol. 40, no. 10, pp. 1300–1307, 2014. View at Google Scholar
  82. S. Kobierski, K. Ofori-Kwakye, R. H. Müller, and C. M. Keck, “Resveratrol nanosuspensions for dermal application—production, characterization, and physical stability,” Pharmazie, vol. 64, no. 11, pp. 741–747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Teskač and J. Kristl, “The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol,” International Journal of Pharmaceutics, vol. 390, no. 1, pp. 61–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Jose, S. S. Anju, T. A. Cinu, N. A. Aleykutty, S. Thomas, and E. B. Souto, “In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery,” International Journal of Pharmaceutics, vol. 474, no. 1-2, pp. 6–13, 2014. View at Publisher · View at Google Scholar
  85. C. Bonechi, S. Martini, L. Ciani et al., “Using liposomes as carriers for polyphenolic compounds: the case of Trans-resveratrol,” PLoS ONE, vol. 7, no. 8, Article ID e41438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Pangeni, J. K. Sahni, J. Ali, S. Sharma, and S. Baboota, “Resveratrol: review on therapeutic potential and recent advances in drug delivery,” Expert Opinion on Drug Delivery, vol. 11, no. 8, pp. 1285–1298, 2014. View at Publisher · View at Google Scholar
  87. R. Z. Ahmed, G. Patil, and Z. Zaheer, “Nanosponges—a completely new nano-horizon: pharmaceutical applications and recent advances,” Drug Development and Industrial Pharmacy, vol. 39, no. 9, pp. 1263–1272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, “Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study,” AAPS PharmSciTech, vol. 12, no. 1, pp. 279–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Pund, R. Thakur, U. More, and A. Joshi, “Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy,” Colloids and Surfaces B: Biointerfaces, vol. 120, pp. 110–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. C.-H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.-L. Beaudeux, “Resveratrol bioavailability and toxicity in humans,” Molecular Nutrition and Food Research, vol. 54, no. 1, pp. 7–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Nunes, L. Almeida, J.-F. Rocha et al., “Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects,” Journal of Clinical Pharmacology, vol. 49, no. 12, pp. 1477–1482, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Sessa, M. L. Balestrieri, G. Ferrari et al., “Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems,” Food Chemistry, vol. 147, pp. 42–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. J. M. Planas, I. Alfaras, H. Colom, and M. E. Juan, “The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters,” Archives of Biochemistry and Biophysics, vol. 527, no. 2, pp. 67–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. A. R. Neves, M. Lúcio, S. Martins, J. L. C. Lima, and S. Reis, “Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability,” International Journal of Nanomedicine, vol. 8, pp. 177–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, “Clinical trials of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 161–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. D. O. Kennedy, E. L. Wightman, J. L. Reay et al., “Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation,” The American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1590–1597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Mecocci and M. C. Polidori, “Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1822, no. 5, pp. 631–638, 2012. View at Publisher · View at Google Scholar · View at Scopus